Enanta Pharmaceuticals Doses First Subject in a Phase 1 Clinical Study of EDP-721, Its Oral Hepatitis B Virus RNA Destabilizer
Retrieved on:
Monday, August 16, 2021
Health, Infectious Diseases, Other Health, Clinical Trials, Pharmaceutical, Biotechnology, European Association for the Study of the Liver, NUC, Trial of the century, Nuc, NASDAQ, RNA, U.S. Securities and Exchange Commission, Drug discovery, Glecaprevir/pibrentasvir, Blood, Child, Membrane protein, Fatty liver disease, RSV, EASL, Human, Patent, Respiratory syncytial virus, Degenerative disease, Hepatitis B, COVID-19, NASH, Pharmacokinetics, Research, Marketing, Security (finance), AbbVie, Recycling, Patient, Hepatocyte, Medication, Risk, Association, Conditional sentence, Severe acute respiratory syndrome coronavirus 2, Institute of Liver and Biliary Sciences, Transcriptome, Hepatitis B virus, Safety, AAV, Industry, HCV, HBV, Vaccine, Pharmaceutical industry, Hepatitis B Virus, Enanta, HEPATITIS B VIRUS, ENANTA
We are pleased to advance our HBV program by dosing the first subject in our Phase 1 clinical study of EDP-721, an orally administered HBV RNA destabilizer that has the potential to reduce S antigen.
Key Points:
- We are pleased to advance our HBV program by dosing the first subject in our Phase 1 clinical study of EDP-721, an orally administered HBV RNA destabilizer that has the potential to reduce S antigen.
- The current standard of care for chronic HBV involves nucleoside reverse transcriptase inhibitors, or NUCs, which can suppress HBV replication.
- This two-part Phase 1a/b study will initially evaluate the safety, tolerability, and pharmacokinetics of EDP-721 in single and multiple ascending oral doses in healthy volunteers.
- Enantas research and development efforts have produced clinical candidates for the following disease targets: respiratory syncytial virus (RSV), hepatitis B virus (HBV), non-alcoholic steatohepatitis (NASH), and SARS-CoV-2 (COVID-19).